Symptom severity and its effect on health-related quality of life over time in patients with pulmonary hypertension: a multisite longitudinal cohort study

Janelle Yorke, Christi Deaton, Malcolm Campbell, Linda McGowen, Paul Sephton, David G Kiely, Iain Armstrong, Janelle Yorke, Christi Deaton, Malcolm Campbell, Linda McGowen, Paul Sephton, David G Kiely, Iain Armstrong

Abstract

Introduction: The aim of this cohort study was to examine health-related quality of life (HRQoL) and symptomatology in patients with pulmonary hypertension (PH) and explore factors that influence its evolution over time.

Methods: A prospective longitudinal multisite cohort study. Participants were recruited from specialist UK PH centres and completed a questionnaire pack at baseline, 6, 12 and 18 months to assess HRQoL (emPHasis-10), dyspnoea, fatigue, sleep, anxiety and depression.

Results: 185 patients entered the study at baseline and 126 (68%) completed month 18. At baseline, patients had significant impairment of HRQoL, anxiety, depression, dyspnoea and severe fatigue. No significant changes, apart from a reduction in the Hospital Anxiety and Depression Scale-Anxiety score (P=0.04), were observed over 18 months. Depression and dyspnoea were predictors of HRQoL (P=0.002 and P=0.03, respectively). Oxygen use was also associated with diminished HRQoL and increased symptom severity.

Conclusion: Patients with PH experience high levels of symptom severity and the negative impact on HRQoL was unchanged over time. The use of oxygen therapy, in particular, was associated with a significant impact on HRQoL. Further study of factors impacting HRQoL and interventions that target a combination of physiological and psychosocial consequences of living with PH are needed.

Keywords: primary pulmonary hypertension; psychology.

Conflict of interest statement

Competing interests: None declared.

References

    1. Galiè N, Humbert M, Vachiery J-L, et al. . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2015;46:903–75.
    1. Armstrong I, Rochnia N, Harries C, et al. . The trajectory to diagnosis with pulmonary arterial hypertension: a qualitative study. BMJ Open 2012;2:e000806
    1. Delcroix M, Howard L. Pulmonary arterial hypertension: the burden of disease and impact on quality of life. Eur Respir Rev 2015;24:621–9.
    1. Cenedese E, Speich R, Dorschner L, et al. . Measurement of quality of life in pulmonary hypertension and its significance. Eur Respir J 2006;28:808–15.
    1. Löwe B, Gräfe K, Ufer C, et al. . Anxiety and depression in patients with pulmonary hypertension. Psychosom Med 2004;66:831–6.
    1. Shafazand S, Goldstein MK, Doyle RL, et al. . Health-related quality of life in patients with pulmonary arterial hypertension. Chest 2004;126:1452–9.
    1. Taichman DB, Shin J, Hud L, et al. . Health-related quality of life in patients with pulmonary arterial hypertension. Respir Res 2005;6:92
    1. McDonough A, Matura LA, Carroll DL. Symptom experience of pulmonary arterial hypertension patients. Clin Nurs Res 2011;20:120–34.
    1. White J, Hopkins RO, Glissmeyer EW, et al. . Cognitive, emotional, and quality of life outcomes in patients with pulmonary arterial hypertension. Respir Res 2006;7:55
    1. McCollister DH, Beutz M, McLaughlin V, et al. . Depressive symptoms in pulmonary arterial hypertension: prevalence and association with functional status. Psychosomatics 2010;51:339–339.e8.
    1. Verma S, Cardenas-Garcia J, Mohapatra PR, et al. . Depression in pulmonary arterial hypertension and interstitial lung diseases. N Am J Med Sci 2014;6:240–9.
    1. Looper KJ, Pierre A, Dunkley DM, et al. . Depressive symptoms in relation to physical functioning in pulmonary hypertension. J Psychosom Res 2009;66:221–5.
    1. Galiè N, Barberà JA, Frost AE, et al. . Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015;373:834–44.
    1. Pulido T, Adzerikho I, Channick RN, et al. . Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013;369:809–18.
    1. Sitbon O, Channick R, Chin KM, et al. . Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015;373:2522–33.
    1. Yorke J, Armstrong I, Bundock S. Impact of living with pulmonary hypertension: a qualitative exploration. Nurs Health Sci 2014;16:454–60.
    1. U.S. Food and Drug Administration (FDA). The voice of the patient. A series of reports from the U.S. Food and Drug Administration’s (FDA’s) patient-focused development initiative. Pulmonary arterial hypertension. Last updated Dec 2014 (accessed 25 Jul 2017).
    1. Flattery MP, Pinson JM, Savage L, et al. . Living with pulmonary artery hypertension: patients' experiences. Heart Lung 2005;34:99–107.
    1. Matura LA, McDonough A, Carroll DL. Predictors of health-related quality of life in patients with idiopathic pulmonary arterial hypertension. J Hosp Palliat Nurs 2012;14:283–92.
    1. Matura LA, McDonough A, Carroll DL. Health-related quality of life and psychological states in patients with pulmonary arterial hypertension. J Cardiovasc Nurs 2014;29:178–84.
    1. Matura LA, McDonough A, Carroll DL. Symptom interference severity and health-related quality of life in pulmonary arterial hypertension. J Pain Symptom Manage 2016;51:25–32.
    1. Kukkonen M, Puhakka A, Halme M. Quality of life among pulmonary hypertension patients in Finland. Eur Clin Respir J 2016;3:26405
    1. European Pulmonary Hypertension Association (PHA). The impact of pulmonary arterial hypertension (PAH) on the lives of patients and carers: results from an international survey. last updated Sep 2012 (accessed 25 Jul 2017).
    1. Mathai SC, Suber T, Khair RM, et al. . Health-related quality of life and survival in pulmonary arterial hypertension. Ann Am Thorac Soc 2016;13:31–9.
    1. Blok IM, van Riel AC, Schuuring MJ, et al. . Decrease in quality of life predicts mortality in adult patients with pulmonary arterial hypertension due to congenital heart disease. Neth Heart J 2015;23:278–84.
    1. Rubenfire M, Lippo G, Bodini BD, et al. . Evaluating health-related quality of life, work ability, and disability in pulmonary arterial hypertension: an unmet need. Chest 2009;136:597–603.
    1. Tabachnik BG, Fidell LS. Using multivariate statistics. 4th Edn Needham Heights MA: Allyn and Bacon, 2001.
    1. Jason LA, Evans M, Brown M, et al. . Fatigue scales and chronic fatigue syndrome: issues of sensitivity and specificity. Disabil Stud Q 2011;31
    1. Stewart AL, Hays RD, Ware JE. The MOS short-form general health survey. Reliability and validity in a patient population. Med Care 1988;26:724–32.
    1. Talwar A, Sahni S, Kim EJ, et al. . Dyspnea, depression and health related quality of life in pulmonary arterial hypertension patients. J Exerc Rehabil 2015;11:259–65.
    1. Kellner R, Samet J, Pathak D. Dyspnea, anxiety, and depression in chronic respiratory impairment. Gen Hosp Psychiatry 1992;14:20–8.
    1. Cullen DL, Stiffler D. Long-term oxygen therapy: review from the patients' perspective. Chron Respir Dis 2009;6:141–7.
    1. Lacasse Y, Bernard S, Martin S, et al. . Utility scores in patients with oxygen-dependent COPD: a case-control study. COPD 2015;12:510–5.
    1. Arnold E, Bruton A, Donovan-Hall M, et al. . Ambulatory oxygen: why do COPD patients not use their portable systems as prescribed? A qualitative study. BMC Pulm Med 2011;11:9
    1. Goldbart J, Yohannes AM, Woolrych R, et al. . ’It is not going to change his life but it has picked him up': a qualitative study of perspectives on long term oxygen therapy for people with chronic obstructive pulmonary disease. Health Qual Life Outcomes 2013;11:124
    1. Khor YH, Goh NSL, McDonald CF, et al. . Oxygen therapy for interstitial lung disease. A mismatch between patient expectations and experiences. Ann Am Thorac Soc 2017;14:888–95.
    1. U.S. Food and Drug Administration (FDA). The voice of the patient. A series of reports from the U.S. Food and Drug Administration’s (FDA’s) patient-focused drug development initiative. Idiopathic pulmonary fibrosis. last updated Mar 2015 (accessed 25 Jul 2017).
    1. Yorke J, Corris P, Gaine S, et al. . emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension. Eur Respir J 2014;43:1106–13.
    1. Yorke J, Moosavi SH, Shuldham C, et al. . Quantification of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12. Thorax 2010;65:21–6.
    1. Krupp LB, LaRocca NG, Muir-Nash J, et al. . The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121–3.
    1. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361–70.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever